Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

Clinical Infectious Diseases

Volumn 63, Issue 5, 2016, Pages e61-e111

  Kalil, Andre C ^a   Metersky, Mark L ^b   Klompas, Michael ^c,d   Muscedere, John ^e   Sweeney, Daniel A ^f   Palmer, Lucy B ^g   Napolitano, Lena M ^h   O'Grady, Naomi P ⁱ   Bartlett, John G ^j   Carratalà, Jordi ^k   El Solh, Ali A ^l   Ewig, Santiago ^m   Fey, Paul D ⁿ   File, Thomas M ^o   Restrepo, Marcos I ^p   Roberts, Jason A ^q,r   Waterer, Grant W ^s   Cruse, Peggy ^t   Knight, Shandra L ^t   Brozek, Jan L ^u  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^e QUEEN S UNIVERSITY   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g STONY BROOK UNIVERSITY   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l UNIVERSITY AT BUFFALO   (United States)

^m Augusta Kranken Anstalt   (Germany)

ⁿ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^o SUMMA HEALTH SYSTEM   (United States)

^p VETERANS AFFAIRS MEDICAL CENTER   (United States)

^q UNIVERSITY OF QUEENSLAND   (Australia)

^r ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^s UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^t DEPARTMENT OF MEDICINE   (United States)

^u MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CLINICAL DECISION MAKING; COLONY FORMING UNIT; COMBINATION DRUG THERAPY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; LUNG INFECTION; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR DIAGNOSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; TRACHEOBRONCHITIS; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; VENTILATOR ASSOCIATED TRACHEOBRONCHITIS; ADULT; BACTERIAL PNEUMONIA; CROSS INFECTION; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; UNITED STATES;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; UNITED STATES;

EID: 84995377035     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw353     Document Type: Review

References (364)

1. American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA). Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
3. US Food and Drug Administration (FDA). Information for healthcare professionals: colistimethate (marketed as Coly-Mycin M and generic products). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm. Accessed September 2014.
4. Magill SS, Edwards JR, Fridkin SK; Emerging Infections Program Healthcare-Associated Infections Antimicrobial Use Prevalence Survey Team. Survey of health care-associated infections. N Engl J Med 2014; 370:2542-3.
5. Dudeck MA, Weiner LM, Allen-Bridson K, et al. National Healthcare Safety Network (NHSN) report, data summary for 2012, device-associated module. Am J Infect Control 2013; 41:1148-66.
6. Dudeck MA, Horan TC, Peterson KD, et al. National Healthcare Safety Network (NHSN) report, data summary for 2009, device-associated module. Am J Infect Control 2011; 39:349-67.
7. Wang Y, Eldridge N, Metersky ML, et al. National trends in patient safety for four common conditions, 2005-2011. N Engl J Med 2014; 370:341-51.
8. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013; 13:665-71.
9. Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis 2010; 51(suppl 1):S120-5.
10. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 2012; 33:250-6.
11. Sopena N, Sabria M; Neunos Study Group. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest 2005; 127:213-9.
12. Esperatti M, Ferrer M, Giunta V, et al. Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. Crit Care Med 2013; 41:2151-61.
13. Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 (suppl 1):S31-40.
14. Klompas M, Branson R, Eichenwald EC, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35(suppl 2):S133-54.
15. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58:330-9.
16. Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 2014; 58:5262-8.
17. Yap V, Datta D, Metersky ML. Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens? Infect Dis Clin North Am 2013; 27:1-18.
18. Jones BE, Jones MM, Huttner B, et al. Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis 2015; 61:1403-10.
19. Valles J, Martin-Loeches I, Torres A, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med 2014; 40:572-81.
20. Hayashi Y, Morisawa K, Klompas M, et al. Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. Clin Infect Dis 2013; 56:471-7.
21. Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS). Supplemental material for the management of adults with hospitalacquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Available at: http://www.idsociety.org/Organ-System/#HospitalAcquired VentilatorAssociatedPneumoniaHAPVAP. Accessed 9 June 2016.
22. Depuydt P, Benoit D, Vogelaers D, et al. Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. Intensive Care Med 2008; 34:675-82.
23. Giantsou E, Liratzopoulos N, Efraimidou E, et al. Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 2005; 31:1488-94.
24. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-9.
25. Gastmeier P, Sohr D, Geffers C, Ruden H, Vonberg RP, Welte T. Early- and lateonset pneumonia: is this still a useful classification? Antimicrob Agents Chemother 2009; 53:2714-8.
26. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117:1434-42.
27. Martin-Loeches I, Deja M, Koulenti D, et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 2013; 39:672-81.
28. Restrepo MI, Peterson J, Fernandez JF, Qin Z, Fisher AC, Nicholson SC. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 2013; 58:1220-5.
29. Verhamme KM, De Coster W, De Roo L, et al. Pathogens in early-onset and lateonset intensive care unit-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28:389-97.
30. Parker CM, Kutsogiannis J, Muscedere J, et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 2008; 23:18-26.
31. George DL, Falk PS, Wunderink RG, et al. Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am J Respir Crit Care Med 1998; 158:1839-47.
32. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160:608-13.
33. Leroy O, Meybeck A, d'Escrivan T, Devos P, Kipnis E, Georges H. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003; 29:2170-3.
34. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13:862-74.
35. Markowicz P, Wolff M, Djedaini K, et al. Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome. Incidence, prognosis, and risk factors. ARDS Study Group. Am J Respir Crit Care Med 2000; 161:1942-8.
36. Chastre J, Trouillet JL, Vuagnat A, et al. Nosocomial pneumonia in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157(4 pt 1):1165-72.
37. Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G. Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med 1987; 13:342-6.
38. Ewig S, Torres A, El-Ebiary M, et al. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. Am J Respir Crit Care Med 1999; 159:188-98.
39. Leroy O, Giradie P, Yazdanpanah Y, et al. Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens. Eur Respir J 2002; 20:432-9.
40. Leroy O, d'Escrivan T, Devos P, Dubreuil L, Kipnis E, Georges H. Hospitalacquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection 2005; 33:129-35.
41. Bouza E, Giannella M, Bunsow E, et al. Ventilator-associated pneumonia due to meticillin-resistant Staphylococcus aureus: risk factors and outcome in a large general hospital. J Hosp Infect 2012; 80:150-5.
42. Moreira MR, Cardoso RL, Almeida AB, Gontijo Filho PP. Risk factors and evolution of ventilator-associated pneumonia by Staphylococcus aureus sensitive or resistant to oxacillin in patients at the intensive care unit of a Brazilian university hospital. Braz J Infect Dis 2008; 12:499-503.
43. Wooten DA, Winston LG. Risk factors for methicillin-resistant Staphylococcus aureus in patients with community-onset and hospital-onset pneumonia. Respir Med 2013; 107:1266-70.
44. Robicsek A, Suseno M, Beaumont JL, Thomson RB Jr, Peterson LR. Prediction of methicillin-resistant Staphylococcus aureus involvement in disease sites by concomitant nasal sampling. J Clin Microbiol 2008; 46:588-92.
45. Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of methicillinresistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 2014; 58:859-64.
46. Sarikonda KV, Micek ST, Doherty JA, Reichley RM, Warren D, Kollef MH. Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment. Crit Care Med 2010; 38:1991-5.
47. Montero M, Sala M, Riu M, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study. Eur J Clin Microbiol Infect Dis 2010; 29:335-9.
48. Agbaht K, Diaz E, Munoz E, et al. Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: a study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia. Crit Care Med 2007; 35:2064-70.
49. Kunac A, Sifri ZC, Mohr AM, Horng H, Lavery RF, Livingston DH. Bacteremia and ventilator-associated pneumonia: a marker for contemporaneous extra-pulmonic infection. Surg Infect (Larchmt) 2014; 15:77-83.
50. Luna CM, Videla A, Mattera J, et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999; 116:1075-84.
51. O'Keefe GE, Caldwell E, Cuschieri J, Wurfel MM, Evans HL. Ventilator-associated pneumonia: bacteremia and death after traumatic injury. J Trauma Acute Care Surg 2012; 72:713-9.
52. DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005; 128:1414-22.
53. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355:2619-30.
54. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132:621-30.
55. Ruiz M, Torres A, Ewig S, et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 2000; 162:119-25.
56. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med 1998; 157:371-6.
57. Sole Violan J, Fernandez JA, Benitez AB, Cardenosa Cendrero JA, Rodriguez de Castro F. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Crit Care Med 2000; 28:2737-41.
58. Berton DC, Kalil AC, Teixeira PJ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev 2014; 10:Cd006482.
59. Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med 1995; 152(6 pt 1):1982-91.
60. Marquette CH, Copin MC, Wallet F, et al. Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. Am J Respir Crit Care Med 1995; 151:1878-88.
61. Torres A, el-Ebiary M, Padro L, et al. Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortempulmonary biopsy. AmJ Respir Crit Care Med 1994; 149(2 pt 1):324-31.
62. Balthazar AB, Von Nowakonski A, De Capitani EM, Bottini PV, Terzi RG, Araujo S. Diagnostic investigation of ventilator-associated pneumonia using bronchoalveolar lavage: comparative study with a postmortem lung biopsy. Braz J Med Biol Res 2001; 34:993-1001.
63. Sole-Violan J, Rodriguez de Castro F, Rey A, et al. Comparison of bronchoscopic diagnostic techniques with histological findings in brain dead organ donors without suspected pneumonia. Thorax 1996; 51:929-31.
64. Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax 1999; 54:867-73.
65. Kirtland SH, Corley DE, Winterbauer RH, et al. The diagnosis of ventilatorassociated pneumonia: a comparison of histologic, microbiologic, and clinical criteria. Chest 1997; 112:445-57.
66. Bregeon F, Papazian L, Thomas P, et al. Diagnostic accuracy of protected catheter sampling in ventilator-associated bacterial pneumonia. Eur Respir J 2000; 16:969-75.
67. Chastre J, Viau F, Brun P, et al. Prospective evaluation of the protected specimen brush for the diagnosis of pulmonary infections in ventilated patients. Am Rev Respir Dis 1984; 130:924-9.
68. Raman K, Nailor MD, Nicolau DP, Aslanzadeh J, Nadeau M, Kuti JL. Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures. Crit Care Med 2013; 41:1656-63.
69. Jorgensen JH, Pfaller MA, Carroll KC, et al. Manual of clinical microbiology. 11th edn. Washington: American Society of Microbiology, 2015.
70. Bonten MJ, Bergmans DC, Stobberingh EE, et al. Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. Am J Respir Crit Care Med 1997; 156:1820-4.
71. Brun-Buisson C, Fartoukh M, Lechapt E, et al. Contribution of blinded, protected quantitative specimens to the diagnostic and therapeutic management of ventilator-associated pneumonia. Chest 2005; 128:533-44.
72. Marik PE, Lynott J, Croxton M, Palmer E, Miller L, Zaloga GP. The effect of blind-protected specimen brush sampling on antibiotic use in patients with suspected ventilator-associated pneumonia. J Intensive Care Med 2001; 16:42-6.
73. Meduri GU, Wunderink RG, Leeper KV, Beals DH. Management of bacterial pneumonia in ventilated patients. Protected bronchoalveolar lavage as a diagnostic tool. Chest 1992; 101:500-8.
74. Babcock HM, Zack JE, Garrison T, Trovillion E, Kollef MH, Fraser VJ. Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location. Infect Control Hosp Epidemiol 2003; 24:853-8.
75. Baker AM, Bowton DL, Haponik EF. Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantitative bronchoscopic cultures. Chest 1995; 107:85-95.
76. Chastre J, Luyt CE, Combes A, Trouillet JL. Use of quantitative cultures and reduced duration of antibiotic regimens for patients with ventilator-associated pneumonia to decrease resistance in the intensive care unit. Clin Infect Dis 2006; 43(suppl 2):S75-81.
77. Combes A, Luyt CE, Trouillet JL, Chastre J. Controversies in ventilator-associated pneumonia. Semin Respir Crit Care Med 2010; 31:47-54.
78. Croce MA, Fabian TC, Waddle-Smith L, et al. Utility of Gram's stain and efficacy of quantitative cultures for posttraumatic pneumonia: a prospective study. Ann Surg 1998; 227:743-51; discussion 51-5.
79. Dreyfuss D, Mier L, Le Bourdelles G, et al. Clinical significance of borderline quantitative protected brush specimen culture results. Am Rev Respir Dis 1993; 147:946-51.
80. Fujitani S, Yu VL. Quantitative cultures for diagnosing ventilator-associated pneumonia: a critique. Clin Infect Dis 2006; 43(suppl 2):S106-13.
81. Giantsou E, Liratzopoulos N, Efraimidou E, et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007; 33:1533-40.
82. Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. Diagnosis of ventilator-associated pneumonia: controversies and working toward a gold standard. Curr Opin Infect Dis 2013; 26:140-50.
83. Heyland DK, Cook DJ, Marshall J, et al. The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Canadian Critical Care Trials Group. Chest 1999; 115:1076-84.
84. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005; 128:2706-13.
85. Malhotra AK, Riaz OJ, Duane TM, et al. Subthreshold quantitative bronchoalveolar lavage: clinical and therapeutic implications. J Trauma 2008; 65:580-8.
86. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32:2183-90.
87. Rodriguez de Castro F, Sole-Violan J, Aranda Leon A, et al. Do quantitative cultures of protected brush specimens modify the initial empirical therapy in ventilated patients with suspected pneumonia? Eur Respir J 1996; 9:37-41.
88. Sterling TR, Ho EJ, Brehm WT, Kirkpatrick MB. Diagnosis and treatment of ventilator-associated pneumonia-impact on survival. A decision analysis. Chest 1996; 110:1025-34.
89. Herer B, Fuhrman C, Gazevic Z, Cabrit R, Chouaid C. Management of nosocomial pneumonia on a medical ward: a comparative study of outcomes and costs of invasive procedures. Clin Microbiol Infect 2009; 15:165-72.
90. Dorca J, Manresa F, Esteban L, et al. Efficacy, safety, and therapeutic relevance of transthoracic aspiration with ultrathin needle in nonventilated nosocomial pneumonia. Am J Respir Crit Care Med 1995; 151:1491-6.
91. Dalhoff K, Braun J, Hollandt H, Lipp R, Wiessmann KJ, Marre R. Diagnostic value of bronchoalveolar lavage in patients with opportunistic and nonopportunistic bacterial pneumonia. Infection 1993; 21:291-6.
92. Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011; 184:1409-17.
93. Pereira W Jr, Kovnat DM, Snider GL. A prospective cooperative study of complications following flexible fiberoptic bronchoscopy. Chest 1978; 73:813-6.
94. Gibson PG, Breit SN, Bryant DH. Hypoxia during bronchoalveolar lavage. Aust N Z J Med 1990; 20:39-43.
95. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res 2000; 49(suppl 1):S57-61.
96. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605-8.
97. Charles PE, Kus E, Aho S, et al. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 2009; 9:49.
98. Muller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010; 138:121-9.
99. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515-8.
100. Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008; 34:1434-40.
101. Dallas J, Brown SM, Hock K, et al. Diagnostic utility of plasma procalcitonin for nosocomial pneumonia in the intensive care unit setting. Respir Care 2011; 56:412-9.
102. Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008; 31:356-62.
103. Duflo F, Debon R, Monneret G, Bienvenu J, Chassard D, Allaouchiche B. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology 2002; 96:74-9.
104. Liao X, Kang Y. Prognostic value of procalcitonin levels in predicting death for patients with ventilator-associated pneumonia. Intensive Care Med 2010; 36: S102.
105. Zhou CD, Lu ZY, Ren NZ, Zhang GC. Diagnostic value of procalcitonin in ventilator associated pneumonia [in Chinese]. Chin Crit Care Med 2006; 18:370-2.
106. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011; 39:2048-58.
107. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164:4991-5.
108. Bopp C, Hofer S, Bouchon A, Zimmermann JB, Martin E, Weigand MA. Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. Eur J Anaesthesiol 2009; 26:504-7.
109. Ferat-Osorio E, Wong-Baeza I, Esquivel-Callejas N, et al. Triggering receptor expressed on myeloid cells-1 expression on monocytes is associated with inflammation but not with infection in acute pancreatitis. Crit Care 2009; 13:R69.
110. Palazzo SJ, Simpson TA, Simmons JM, Schnapp LM. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a diagnostic marker of ventilator-associated pneumonia. Respir Care 2012; 57:2052-8.
111. Anand NJ, Zuick S, Klesney-Tait J, Kollef MH. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. Chest 2009; 135:641-7.
112. Determann RM, Millo JL, Gibot S, et al. Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilatorassociated pneumonia. Intensive Care Med 2005; 31:1495-500.
113. Horonenko G, Hoyt JC, Robbins RA, et al. Soluble triggering receptor expressed on myeloid cell-1 is increased in patients with ventilator-associated pneumonia: a preliminary report. Chest 2007; 132:58-63.
114. Ramirez P, Kot P, Marti V, et al. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in patients with acute respiratory distress syndrome and abdominal diseases: a preliminary observational study. Crit Care 2011; 15:R50.
115. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350:451-8.
116. Oppert M, Reinicke A, Muller C, Barckow D, Frei U, Eckardt KU. Elevations in procalcitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation 2002; 53:167-70.
117. Fartoukh M, Maitre B, Honore S, Cerf C, Zahar JR, Brun-Buisson C. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med 2003; 168:173-9.
118. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006; 27:158-64.
119. Shan J, Chen HL, Zhu JH. Diagnostic accuracy of clinical pulmonary infection score for ventilator-associated pneumonia: a meta-analysis. Respir Care 2011; 56:1087-94.
120. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162(2 pt 1):505-11.
121. Veinstein A, Brun-Buisson C, Derrode N, et al. Validation of an algorithm based on direct examination of specimens in suspected ventilator-associated pneumonia. Intensive Care Med 2006; 32:676-83.
122. Nseir S, Di Pompeo C, Soubrier S, et al. Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case-control study. Crit Care 2005; 9:R238-45.
123. Nseir S, Favory R, Jozefowicz E, et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Crit Care 2008; 12:R62.
124. Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med 2014; 189:1225-33.
125. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilatorassociated tracheobronchitis in the intensive care unit. Crit Care Med 2008; 36:2008-13.
126. Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002; 20:1483-9.
127. Nseir S, Di Pompeo C, Soubrier S, et al. Outcomes of ventilated COPD patients with nosocomial tracheobronchitis: a case-control study. Infection 2004; 32:210-6.
128. Dallas J, Skrupky L, Abebe N, Boyle WA 3rd, Kollef MH. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 2011; 139:513-8.
129. Martin-Loeches I, Povoa P, Rodriguez A, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respir Med 2015; 3:859-68.
130. Nseir S, Martin-Loeches I, Makris D, et al. Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia. Crit Care 2014; 18:R129.
131. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006; 130:787-93.
132. Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000; 49:638-45; discussion 45-6.
133. Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, McGowan JE Jr. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001; 33:324-30.
134. Clinical and Laboratory Standards Institute. Analysis and presentation of cumulative antimicrobial suseptibility test data. Approved guideline. 4th ed. CLSI document M39-A4. Wayne, PA: CLSI, 2014.
135. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
136. Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015; 15:225-34.
137. Sader HS, Rhomberg PR, Jones RN. In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamaseproducing Pseudomonas aeruginosa and Acinetobacter baumannii. J Chemother 2005; 17:622-7.
138. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14.
139. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51(suppl 1): S81-7.
140. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-20.
141. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 2008; 23:91-100.
142. Muscedere JG, Shorr AF, Jiang X, Day A, Heyland DK; Canadian Critical Care Trials Group. The adequacy of timely empiric antibiotic therapy for ventilatorassociated pneumonia: an important determinant of outcome. J Crit Care 2012; 27:322.e7-14.
143. Rello J, Ulldemolins M, Lisboa T, et al. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 2011; 37:1332-9.
144. Vardakas KZ, Mavros MN, Roussos N, Falagas ME. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc 2012; 87:349-63.
145. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011; 139:1148-55.
146. Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013; 3:e003912.
147. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010; 38:1802-8.
148. Torres A, Rubinstein E, Corey GR, Stryjewski ME, Barriere SL. Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother 2014; 69:1119-26.
149. Pasquale TR, Tan MJ, Trienski TL, File TM Jr. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients. J Chemother 2015; 27:29-34.
150. Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother 2016; 71:152-5.
151. Cepeda JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53:345-55.
152. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections. J Antimicrob Chemother 2004; 53:335-44.
153. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31-40.
154. Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother 2014; 58:2030-7.
155. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140-51.
156. Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; 59:51-61.
157. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089-96.
158. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16:R218.
159. Alvarez Lerma F; Serious Infection Study Group. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13:70-81.
160. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27:493-502.
161. Sieger B, Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997; 25:1663-70.
162. Heyland DK, Dodek P, Muscedere J, Day A, Cook D; Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36:737-44.
163. Polk HC Jr, Livingston DH, Fry DE, et al. Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial. Arch Surg 1997; 132:1086-92.
164. Croce MA, Fabian TC, Stewart RM, et al. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J Trauma 1993; 35:303-9; discussion 309-11.
165. Reeves JH, Russell GM, Cade JF, McDonald M. Comparison of ceftriaxone with cefotaxime in serious chest infections. Chest 1989; 96:1292-7.
166. Thomas PD, Daly S, Misan G, Steele T. Comparison of the efficacy and adverse effect profile of cefotaxime, 3 g/day, and ceftriaxone, 2 g/day, in the treatment of nosocomial lower respiratory tract infections in ICU patients. Eur Respir Rev 1994; 4:321-8.
167. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38:547-57.
168. Shorr AF, Zadeikis N, Jackson WL, et al. Levofloxacin for treatment of ventilatorassociated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis 2005; 40(suppl 2):S123-9.
169. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506.
170. Kljucar S, Heimesaat M, von Pritzbuer E, Olms K. Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients [in German]. Infection 1987; 15(suppl 4): S185-91.
171. Damas P, Garweg C, Monchi M, et al. Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. Crit Care 2006; 10:R52.
172. Hartenauer U, Weilemann LS, Bodmann KF, Ritzerfeld WW, Asmus S, Koch EM. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect 1990; 15 (suppl A):61-4.
173. Torres A, Bauer TT, Leon-Gil C, et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000; 55:1033-9.
174. Beaucaire G. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. J Chemother 1995; 7(suppl 2):165-73.
175. Beaucaire G, Nicolas MH, Martin C, et al. Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study [in French]. Ann Fr Anesth Reanim 1999; 18:186-95.
176. Manhold C, von Rolbicki U, Brase R, et al. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study. Intensive Care Med 1998; 24:1327-30.
177. Saginur R, Garber G, Darling G, et al. Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia. Can J Infect Dis 1997; 8:89-94.
178. Ahmed SM, Choudhary J, Ahmed M, Arora V, Parul, Ali S. Treatment of ventilator-associated pneumonia with piperacillin-tazobactum and amikacin vs cefepime and levofloxacin: a randomized prospective study. Indian J Crit Care Med 2007; 11:117-21.
179. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, openlabel, multicenter study. Curr Med Res Opin 2008; 24:2113-26.
180. Brun-Buisson C, Sollet JP, Schweich H, Briere S, Petit C. Treatment of ventilatorassociated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 1998; 26:346-54.
181. Brown RB, Lemeshow S, Teres D. Moxalactam vs carbenicillin plus tobramycin: treatment of nosocomial gram-negative bacillary pneumonias in non-neutropenic patients. Curr Ther Res 1984; 36:557-64.
182. Maskin B, Fontan PA, Spinedi EG, Gammella D, Badolati A. Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with gram-negative nosocomial pneumonia. Crit Care Med 2002; 30:349-54.
183. Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006; 100:1554-65.
184. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54: 670-80.
185. Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant gram-negative bacterial infections. Int J Antimicrob Agents 2015; 46:266-71.
186. Gottesman T, Yossepowitch O, Lerner E, et al. The accuracy of Gram stain of respiratory specimens in excluding Staphylococcus aureus in ventilator-associated pneumonia. J Crit Care 2014; 29:739-42.
187. Tetenta S, Metersky ML. Tracheal aspirate Gram stain has limited sensitivity and specificity for detecting Staphylococcus aureus. Respirology 2011; 16:86-9.
188. O'Horo JC, Thompson D, Safdar N. Is the Gram stain useful in the microbiologic diagnosis of VAP? A meta-analysis. Clin Infect Dis 2012; 55:551-61.
189. McKinnell JA, Huang SS, Eells SJ, Cui E, Miller LG. Quantifying the impact of extranasal testing of body sites for methicillin-resistant Staphylococcus aureus colonization at the time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol 2013; 34:161-70.
190. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillinresistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39: 776-82.
191. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851-63.
192. Swanson JM, Wells DL. Empirical antibiotic therapy for ventilator-associated pneumonia. Antibiotics 2013; 2:339-51.
193. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-9.
194. Joffe AR, Muscedere J, Marshall JC, Su Y, Heyland DK; Canadian Critical Care Trials Group. The safety of targeted antibiotic therapy for ventilator-associated pneumonia: a multicenter observational study. J Crit Care 2008; 23:82-90.
195. Hibbard ML, Kopelman TR, O'Neill PJ, et al. Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia. Surg Infect (Larchmt) 2010; 11:427-32.
196. Joung MK, Lee JA, Moon SY, et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 2011; 15:R79.
197. Weiss CH, Dibardino D, Rho J, Sung N, Collander B, Wunderink RG. A clinical trial comparing physician prompting with an unprompted automated electronic checklist to reduce empirical antibiotic utilization. Crit Care Med 2013; 41:2563-9.
198. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e10-52.
199. Mentzelopoulos SD, Pratikaki M, Platsouka E, et al. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrugresistant Pseudomonas aeruginosa. Intensive Care Med 2007; 33:1524-32.
200. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:1983-6.
201. Marchaim D, Chopra T, Bhargava A, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012; 33:817-30.
202. Miyawaki K, Miwa Y, Seki M, Asari S, Tomono K, Kurokawa N. Correlation between the consumption of meropenem or doripenem and meropenem susceptibility of Pseudomonas aeruginosa in a university hospital in Japan. Biol Pharm Bull 2012; 35:946-9.
203. McDougall DA, Morton AP, Playford EG. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia. J Antimicrob Chemother 2013; 68:457-60.
204. Routsi C, Pratikaki M, Platsouka E, et al. Risk factors for carbapenem-resistant gram-negative bacteremia in intensive care unit patients. Intensive Care Med 2013; 39:1253-61.
205. Pena C, Guzman A, Suarez C, et al. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother 2007; 51:1967-71.
206. Ogutlu A, Guclu E, Karabay O, Utku AC, Tuna N, Yahyaoglu M. Effects of carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients. Ann Clin Microbiol Antimicrob 2014; 13:7.
207. Armand-Lefevre L, Angebault C, Barbier F, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013; 57:1488-95.
208. Moreira MR, Guimaraes MP, Rodrigues AA, Gontijo Filho PP. Antimicrobial use, incidence, etiology and resistance patterns in bacteria causing ventilator-associated pneumonia in a clinical-surgical intensive care unit. Rev Soc Bras Med Trop 2013; 46:39-44.
209. Swaminathan M, Sharma S, Poliansky Blash S, et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 2013; 34:809-17.
210. European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report: antimicrobial resistance and healthcare-associated infections 2014. Stockholm: ECDC, 2015.
211. Jacob J, Klein E, Laxminarayan R, et al. Carbapenem resistant enterobactereciae. MMWR Morb Mortal Wkly Rep 2013; 62:165-70.
212. Thaden JT, Lewis SS, Hazen KC, et al. Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol 2014; 35:978-83.
213. Luna CM, Sarquis S, Niederman MS, et al. Is a strategy based on routine endotracheal cultures the best way to prescribe antibiotics in ventilator-associated pneumonia? Chest 2013; 144:63-71.
214. Yakovlev SV, Stratchounski LS, Woods GL, et al. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis 2006; 25:633-41.
215. Alsuraikh M, Hamdy G. Incidence, risk factors, and causative agents of hospital acquired pneumonia (nosocomial pneumonia) in adult hospitalized patients in medical wards of a general hospital in Kuwait. Kuwait Med J 2008; 40:297-300.
216. Avci M, Ozgenc O, Coskuner A, Bozca B, Kidak L, Mermut G. Hospital-acquired pneumonia in nonintensive care unit wards. Turk J Med Sci 2010; 40:357-63.
217. Cakir Edis E, Hatipoglu ON, Yilmam I, Eker A, Tansel O, Sut N. Hospital-acquired pneumonia developed in non-intensive care units. Respiration 2009; 78:416-22.
218. Espejo E, Andres M, Torviso J, et al. Hospital-acquired bacteraemic pneumonia in non-ventilated patients. In: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th International Congress of Chemotherapy (ICC) Posters 2011: S478.
219. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-62.
220. Giannella M, Pinilla B, Capdevila JA, et al. Pneumonia treated in the internal medicine department: focus on healthcare-associated pneumonia. Clin Microbiol Infect 2012; 18:786-94.
221. Piskin N, Aydemir H, Oztoprak N, et al. Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: risk factors and impact on outcomes. BMC Infect Dis 2012; 12:268.
222. Esperatti M, Ferrer M, Theessen A, et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 2010; 182:1533-9.
223. Maruyama T, Niederman MS, Kobayashi T, et al. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in nonintubated elderly. Respir Med 2008; 102:1287-95.
224. Barreiro-Lopez B, Tricas JM, Mauri E, Quintana S, Garau J. Risk factors and prognostic factors in nosocomial pneumonia outside the intensive care units setting [in Spanish]. Enferm Infecc Microbiol Clin 2005; 23:519-24.
225. Takano Y, Sakamoto O, Suga M, Muranaka H, Ando M. Prognostic factors of nosocomial pneumonia in general wards: a prospective multivariate analysis in Japan. Respir Med 2002; 96:18-23.
226. Schussler O, Alifano M, Dermine H, et al. Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med 2006; 173:1161-9.
227. Watanabe A, Yanagihara K, Kohno S, Matsushima T; HAP Study Group. Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of firstline antibiotics in Japan. Intern Med 2008; 47:245-54.
228. Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28:825-31.
229. Kim J, Chung J, Choi S-H, et al. Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Crit Care 2012; 16:1-9.
230. Kohlenberg A, Schwab F, Behnke M, Geffers C, Gastmeier P. Pneumonia associated with invasive and noninvasive ventilation: an analysis of the German nosocomial infection surveillance system database. Intensive Care Med 2010; 36:971-8.
231. Herer B, Fuhrman C, Demontrond D, Gazevic Z, Housset B, Chouaid C. Diagnosis of nosocomial pneumonia in medical ward: repeatability of the protected specimen brush. Eur Respir J 2001; 18:157-63.
232. Edis EC, Hatipoglu ON, Yilmam I, Eker A, Tansel O, Sut N. The importance of pathogen identification in the success of treatment of hospital acquired pneumonias. Turk Toraks Dergisi 2010; 11:155-9.
233. Giunta V, Ferrer M, Esperatti M, et al. ICU-acquired pneumonia with or without etiologic diagnosis: a comparison of outcomes. Crit Care Med 2013; 41:2133-43.
234. Fernandez-Guerrero M, Gudiol F, Rodriguez-Torres A, Arnau C, Valdes L, Vallve C. Nosocomial pneumonia: comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations. Infection 1991; 19 (suppl 6):S320-5.
235. Schmitt DV, Leitner E, Welte T, Lode H. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia-a double blind prospective multicentre study. Infection 2006; 34:127-34.
236. Hoffken G, Barth J, Rubinstein E, Beckmann H; HAP Study Group. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospitalacquired pneumonia. Infection 2007; 35:414-20.
237. Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 2012; 56:1065-72.
238. Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with earlyonset ventilator-associated pneumonia. Clin Pharmacokinet 2003; 42:589-98.
239. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011; 55:2704-9.
240. Anevlavis S, Petroglou N, Tzavaras A, et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009; 59:83-9.
241. Montravers P, Veber B, Auboyer C, et al. Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: results of the Eole study. Crit Care Med 2002; 30:368-75.
242. Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000; 179:436-40.
243. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17:497-504.
244. Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007; 51:3304-10.
245. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health careassociated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107-15.
246. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33:464-8.
247. Lorente L, Jimenez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007; 29:2433-9.
248. Scaglione F, Esposito S, Leone S, et al. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J 2009; 34:394-400.
249. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58:1072-83.
250. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840-51; quiz 59.
251. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41:489-95.
252. Sinnollareddy MG, Roberts MS, Lipman J, Roberts JA. Beta-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. Clin Exp Pharmacol Physiol 2012; 39:489-96.
253. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14:498-509.
254. Lux LJ, Posey RE, Daniels LS, et al. Pharmacokinetic/pharmacodynamic measures for guiding antibiotic treatment for hospital-acquired pneumonia. Rockville, MD: Agency for Healthcare Research and Quality, 2014. Comparative Effectiveness? Reviews, No 136. Available at: http://www.ncbi.nlm.nih.gov/books/NBK266264/. Accessed 5 January 2015.
255. Hallal A, Cohn SM, Namias N, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt) 2007; 8:73-82.
256. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010; 51:1238-44.
257. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010; 16:1230-6.
258. Le Conte P, Potel G, Clementi E, et al. Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study [in French]. Presse Med 2000; 29:76-8.
259. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother 2010; 65:2645-9.
260. Doshi NM, Cook CH, Mount KL, et al. Adjunctive aerosolized colistin for multidrug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC Anesthesiol 2013; 13:45.
261. Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 2013; 144:1768-75.
262. Brown RB, Kruse JA, Counts GW, Russell JA, Christou NV, Sands ML. Doubleblind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother 1990; 34:269-72.
263. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132:761-5.
264. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilatorassociated pneumonia. Chest 2005; 128:545-52.
265. Valcke YJ, Vogelaers DP, Colardyn FA, Pauwels RA. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992; 101:1028-32.
266. Boselli E, Breilh D, Djabarouti S, et al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med 2007; 33:1519-23.
267. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430-6.
268. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30:143-51.
269. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161(3 pt 1):753-62.
270. Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38:175-80.
271. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60:1361-9.
272. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-90.
273. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134:1200-7.
274. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-9.
275. Montedori A, Bonacini MI, Casazza G, et al. Modified versus standard intentionto-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study. Trials 2011; 12:58.
276. US Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee. FDA advisory committee briefing document: telavancin for nosocomial pneumonia, 2012. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329482.pdf. Accessed January 2013.
277. Ramsey KM, Mazer MA. Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant Staphylococcus aureus: caveat emptor. Crit Care Med 2010; 38:326-7.
278. Lahey T. Questionable superiority of linezolid for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: watch where you step. Clin Infect Dis 2012; 55:159-60.
279. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-7.
280. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60:788-94.
281. Adam HJ, Louie L, Watt C, et al. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob Agents Chemother 2010; 54:945-9.
282. Holmes RL, Jorgensen JH. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob Agents Chemother 2008; 52:757-60.
283. Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates. J Clin Microbiol 2011; 49:269-74.
284. Sader HS, Fey PD, Limaye AP, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009; 53:4127-32.
285. van Hal SJ, Barbagiannakos T, Jones M, et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 2011; 66:2284-7.
286. Honda H, Doern CD, Michael-Dunne W Jr, Warren DK. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia. BMC Infect Dis 2011; 11:335.
287. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and metaanalysis. JAMA 2014; 312:1552-64.
288. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66:2386-92.
289. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-7.
290. Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008; 36: 108-17.
291. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-7.
292. Giamarellou H, Mandragos K, Bechrakis P, Pigas K, Bilalis D, Sfikakis P. Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients. J Antimicrob Chemother 1990; 26(suppl B):117-27.
293. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-72.
294. Planquette B, Timsit JF, Misset BY, et al. Pseudomonas aeruginosa ventilator-associated pneumonia. Predictive factors of treatment failure. AmJ Respir Crit Care Med 2013; 188:69-76.
295. Pena C, Gomez-Zorrilla S, Oriol I, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis 2013; 32:413-20.
296. Luyt CE, Aubry A, Lu Q, et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014; 58:1372-80.
297. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm. Accessed 5 January 2015.
298. Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 2010; 10:45.
299. Siempos II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007; 29:548-60.
300. Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J Antimicrob Chemother 1995; 36 (suppl A):145-56.
301. Norrby SR, Finch RG, Glauser M. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group. J Antimicrob Chemother 1993; 31:927-37.
302. Carcas AJ, Garcia-Satue JL, Zapater P, Frias-Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 1999; 65:245-50.
303. Levy J, Baran D, Klastersky J. Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis. J Antimicrob Chemother 1982; 10:227-34.
304. Mombelli G, Coppens L, Thys JP, Klastersky J. Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion. Antimicrob Agents Chemother 1981; 19:72-5.
305. Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30:315-9.
306. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003; 47:2659-62.
307. Rigatto MH, Ribeiro VB, Konzen D, Zavascki AP. Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Infection 2013; 41:321-8.
308. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J Antimicrob Chemother 2004; 54:566-9.
309. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66:2070-4.
310. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. Diagn Microbiol Infect Dis 2015; 83:379-81.
311. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38:1309-13.
312. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35:1888-95.
313. Park SY, Park HJ, Moon SM, et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis 2012; 12:308.
314. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38:1773-85.
315. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; CD003344.
316. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010; 38:1651-64.
317. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012; 25:450-70.
318. Morata L, Cobos-Trigueros N, Martinez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012; 56:4833-7.
319. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-27.
320. Hu Y, Li L, Li W, et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents 2013; 42:492-6.
321. Paul M, Leibovici L. Editorial commentary: combination therapy for Pseudomonas aeruginosa bacteremia: where do we stand? Clin Infect Dis 2013; 57:217-20.
322. Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. Beta-lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 2013; 41:301-10.
323. Pena C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis 2013; 57:208-16.
324. Balakrishnan I, Awad-El-Kariem FM, Aali A, et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011; 66:2628-31.
325. Bassetti M, Righi E, Fasce R, et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamaseproducing organisms in an intensive care unit. J Antimicrob Chemother 2007; 60:433-5.
326. Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R. Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamaseproducing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother 2010; 54:2119-24.
327. Cheng WL, Hsueh PR, Lee CC, et al. Bacteremic pneumonia caused by extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: appropriateness of empirical treatment matters. J Microbiol Immunol Infect 2014; 49:208-15.
328. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-7.
329. Tsai HY, Chen YH, Tang HJ, et al. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis 2014; 80:222-6.
330. Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2014; 69:871-80.
331. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141: 1214-22.
332. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56:432-6.
333. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillinsulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007; 39:38-43.
334. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57:349-58.
335. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425-30.
336. Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrugresistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 2014; 14:102.
337. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-8.
338. Ramasubban S, Majumdar A, Das PS. Safety and efficacy of polymyxin B in multidrug resistant gram-negative severe sepsis and septic shock. Indian J Crit Care Med 2008; 12:153-7.
339. Simsek F, Gedik H, Yildirmak MT, et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? Indian J Med Microbiol 2012; 30:448-52.
340. Kalin G, Alp E, Akin A, Coskun R, Doganay M. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 2014; 42:37-42.
341. Choi HK, Kim YK, Kim HY, Uh Y. Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii. Yonsei Med J 2014; 55:118-25.
342. Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; 8:Cd007577.
343. Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short-vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013; 144:1759-67.
344. Hedrick TL, McElearney ST, Smith RL, Evans HL, Pruett TL, Sawyer RG. Duration of antibiotic therapy for ventilator-associated pneumonia caused by nonfermentative gram-negative bacilli. Surg Infect (Larchmt) 2007; 8:589-97.
345. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98.
346. Fekih Hassen M, Ayed S, Ben Sik Ali H, Gharbi R, Marghli S, Elatrous S. Duration of antibiotic therapy for ventilator-associated pneumonia: comparison of 7 and 10 days. A pilot study [in French]. Ann Fr Anesth Reanim 2009; 28:16-23.
347. Medina J, Perez Protto S, Paciel D, Pontet J, Saldun P, Berro M. Antibiotic treatment for the ventilator-associated pneumonia: 8 vs. 12 days randomized trial preliminary data. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2007:361.
348. Capellier G, Mockly H, Charpentier C, et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS One 2012; 7:e41290.
349. Alvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006; 10:R78.
350. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66:1343-8.
351. Kollef MH. Providing appropriate antimicrobial therapy in the intensive care unit: surveillance vs. de-escalation. Crit Care Med 2006; 34:903-5.
352. Leone M, Bechis C, Baumstarck K, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40:1399-408.
353. Camargo LF. The "de-escalation concept" and antibiotic de-escalation: a missed opportunity? Shock 2013; 39(suppl 1):29-31.
354. Dellit TH, Chan JD, Skerrett SJ, Nathens AB. Development of a guideline for the management of ventilator-associated pneumonia based on local microbiologic findings and impact of the guideline on antimicrobial use practices. Infect Control Hosp Epidemiol 2008; 29:525-33.
355. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a deescalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122:2183-96.
356. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210-8.
357. Lisboa T, Rello J. De-escalation in lower respiratory tract infections. Curr Opin Pulm Med 2006; 12:364-8.
358. Niederman MS, Soulountsi V. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia? Clin Chest Med 2011; 32:517-34.
359. Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012; 55:651-62.
360. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9:CD007498.
361. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34:1364-75.
362. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-74.
363. Pontet J, Paciel D, Olivera W, Bentancourt S, Cancela M, Gervas J. Procalcitonin (PCT) guided antibiotic treatment in ventilator associated pneumonia (VAP). Multi-centre, clinical prospective, randomized-controlled study. Am J Respir Crit Care Med 2007; 175:A212.
364. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15.